Audit: QRS - Rentosertib for Health & Longevity

Audit conducted on 11/09/2026 22:32 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	86
Failed	0
N/A	7
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All 69 populated spans traced to ER passages: protocol cells to Therapeutic Protocol, time cells to Practical Considerations → Time to effect, gates to Key Interactions & Contraindications, tiers to Expected Benefits / Potential Risks & Side Effects, markers and cadence to Monitoring Protocol & Defining Success.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“unvalidated laboratory measures” mirrors the ER’s “never been validated against any health outcome”; “No established target; track change from baseline” mirrors the ER biomarker table.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindication severity preserved; caution-level interactions still carry “(caution)” and trial-level exclusions still carry “(contraindicated in trial)”.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come only from the ER’s “Populations who should avoid rentosertib” list; Key Interactions only from the ER’s interaction bullets; no Benefit- or Risk-Modifying Factor was promoted into a gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, no NCT identifiers, no author names in the QRS. Every drug name (nintedanib, pirfenidone, ketoconazole, clarithromycin, rifampicin, carbamazepine, fluvoxamine, amiodarone, sotalol, warfarin, berberine, curcumin, piperine, licorice) appears in the ER’s interaction bullets for the same fact.
1.6	The QRS does not introduce new attributions.	🟢	“almost all evidence produced by the developer” maps to the ER Conclusion; no new sponsor, society or expert attribution added.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Matches the ER’s restrained, single-trial framing throughout.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Presents the lung-capacity signal and the liver/diarrhea signal side by side without exhortation.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Protocol cells describe trial regimens rather than instructing.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperative or prescriptive constructions; monitoring targets are presented as ranges carried over from the ER table.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	E.g. “failing any means the regimen does not start” is descriptive, not directive.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No occurrence of “you”, “your” or “yourself” anywhere in the file.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Lede uses “scar-forming enzyme”, “blood-protein readings”; technical marker names (ALT, GGT, eGFR, QTcF, FVC, DLCO) are necessary and carried verbatim from the ER monitoring table.
2.8	Information is presented in a concise and very compact manner	🟢	Every ER bullet was reduced to its key fact; mechanistic rationale, magnitudes and citations were dropped across all sections.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by full-text scan; no second-person address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Lede leads with the access and evidence-provenance problem, which is the decision-relevant frame for this audience.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Fasted dosing, the full liver/potassium/ECG gating panel and the multi-visit cadence are all retained rather than softened.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Content density and the 10-marker monitoring table presuppose a proactive reader.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The lede foregrounds “Unapproved everywhere, with no legitimate supply route”, the decisive point for a self-experimenting reader.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	No occurrence of “anti-aging”; the sheet uses “biological age” and “Longevity” (in the title).
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	Lede says “An experimental oral medication”; action_1_sub says “Orally, as a tablet”. No “pill”, “shot” or “taken by mouth” anywhere.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All headings are byte-identical to [qrs_template]; tier labels render as “Medium: “, “Low: “, “Speculative: “ exactly as templated.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 template variable names are present; the repeatable marker_#_* and qualitative_item_# patterns are correctly expanded to marker_1..10 and qualitative_item_1..5.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Structural diff against the template shows changes only inside checklist-governed spans; the website="evidence_review", website="audit" and website="full_review" spans, the CSS block and the footer disclaimer are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No ER source section feeding a QRS section is empty. The empty ER tiers (Benefits High, Risks High, Risks Low) are governed by the more specific items 12.5 and 13.5, which mandate display: none instead of empty-state phrasing.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard regimen”, “Food”, “Baseline biomarkers” match the ER Therapeutic Protocol bold labels verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Protocol labels, gate headings, tier labels and monitoring marker names all reproduce the ER wording.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Zero emoji in the file; the ER’s ⚠️ Conflicted markers were correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Single-page template preserved; every section shows applied condensation — drug example lists trimmed (CYP3A4 inhibitors from four examples to two), all mechanistic rationale and trailing em-dash clauses stripped, monitoring targets and “why” cells shortened against the ER table.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after <!doctype html> on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- on line 3, closing --- on line 13; the preamble text “QRS — Metadata (invisible, parsed by audit tooling)” precedes it and is permitted.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is repeated in the header, lede or footer.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:04" is quoted, and it contains a colon, so quoting is required.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: rentosertib_2026-0911-2020_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.9.11, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0911-2208.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: qrs_filename: rentosertib_2026-0911-2020_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Rentosertib for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Rentosertib for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “09/11/2026” from qrs_creation_date: 2026-0911-2208.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header carries only the templated title and subline; the ER’s “Also known as: ISM001-055, INS018_055” line was correctly not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses ER lines 468–472: mechanism, the single-trial lung-capacity result, the unvalidated aging readouts, the liver/diarrhea signal, and the access and sponsorship problems.
7.2	[at_a_glance] is no longer than 60 words	🟢	58 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to a distinct ER Conclusion sentence; “no legitimate supply route” additionally matches ER Sourcing and Quality.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms at all; “TNIK” rendered as “a scar-forming enzyme”, “proteomic aging clock” as “blood-protein readings looked younger”.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	Refers only to “One short trial” — no name, year, n, or p-value.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No millilitre figures, confidence intervals, or percentages.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All 11 items come from the “Populations who should avoid rentosertib” subsection at ER lines 294–306.
8.2	[stop_items] represent the Contraindications from the ER	🟢	One-to-one mapping: all 11 ER avoidance populations are present, none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	11 <li> elements inside the stop_items span (lines 564–576).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s explanatory parenthetical on cotinine (“a nicotine breakdown product used to verify non-smoking”) and the “human immunodeficiency virus” expansion were correctly compressed; no dash-trailing clauses remain.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“(any Child-Pugh class)”, “1.5× normal”, “3×”, “below 60 mL/min/1.73 m²”, “450 ms (men) or 470 ms (women)”, “within 6 months”, “within 5 years”, “90 days after the last dose” all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in its contraindication bullets; thresholds are written out as “at or above 1.5 times the upper limit of normal”.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names 11 avoidance populations and the section is correctly populated rather than left empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All 14 items come from the interaction bullets at ER lines 266–292.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All 14 ER interaction bullets are represented; none duplicates an item in stop_items.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	14 <li> elements inside the caution_items span (lines 582–597).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every ER mechanism sentence and “Mitigation:” clause was dropped; only the label plus its qualifier parenthetical remains.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Severity class (“caution” / “contraindicated in trial”) retained on all 14 items, and each drug list retained in trimmed form (e.g. “ketoconazole, clarithromycin”; “fluvoxamine, tobacco smoke”; “berberine, high-dose curcumin with piperine”).
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in its interaction bullets; all parentheticals are plain comma- or semicolon-separated lists.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names 14 interactions and the section is correctly populated rather than left empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from ER Therapeutic Protocol (lines 330–358).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose regimen, fasted administration, and the baseline-biomarker entry gate — the three bullets that determine whether and how the regimen is executed.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies well over three actionable aspects; all three action sets are populated.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans populated: “Standard regimen / 60 mg once daily”, “Food / Fasted”, “Baseline biomarkers / Gate entry”, each with an ER-derived sub-line.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	The ER’s Time-to-effect bullet (line 393) names exactly two readouts — lung capacity at 12 weeks and blood proteins by week 4 — and both are covered.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Lung capacity (Medium-tier benefit) precedes blood proteins (Speculative-tier).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	🟢	The third .pcell and its three spans carry style="display: none" with empty content (lines 524–534); no placeholder or empty-state text.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	Both used sets are populated with ER-verbatim content from Practical Considerations.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All tiers map to ER lines 136–176.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present in template order.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	The ER’s Magnitude lines (+98.4 mL, 95% CI, P = 0.0495), the “⚠️ Conflicted” marker and all trial descriptions were dropped; only the five speculative and two graded headings remain.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses remain in any benefits item.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER records no High-tier benefit; line 542 sets benefits_high to style="display: none" with empty content.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All tiers map to ER lines 200–244.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present in template order.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Frequencies (2/18, 13.0%, 23.3 days), the nintedanib confounding discussion and all citations were dropped; four Medium and three Speculative key facts remain.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses remain in any risks item.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER records no High-tier and no Low-tier risk; lines 608 and 615 set risks_high and risks_low to style="display: none" with empty content.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Derived from ER Monitoring Protocol & Defining Success (lines 421–436).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All 10 ER table rows present in ER order: ALT, AST, total bilirubin, GGT, alkaline phosphatase, potassium, eGFR, QTcF, FVC % predicted, DLCO % predicted, with targets carried over verbatim.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Lines 774–777 reproduce the ER’s cadence sentence: liver panel and potassium at weeks 2, 4, 8, 12 then quarterly; ECG at weeks 2, 4, 8, 12, 26, 39, 52; lung function at weeks 4, 12, 26, 39, 52.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Derived from the qualitative-marker list at ER lines 440–444.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All five ER qualitative markers present, with the ER’s trailing em-dash explanations correctly stripped.

Issues 11/09/2026 22:32

Pass rate 100.00%. No issues found.

Issues 11/09/2026 22:19

1. 4.5 — Sheet overruns one A4 page: The populated body runs to roughly twice the printable A4 height — the Key Interactions gate alone wraps to about 22 lines (lines 583–597) and the Monitoring table to 11 multi-line rows (lines 637–769) — so several items still carry length that can be condensed without dropping required content.
2. 9.5 — “high-dose” qualifier dropped: Lines 594 and 595 give “green tea extract” and “curcumin with piperine” where the ER (l.288, l.290) specifies “high-dose green tea extract” and “high-dose curcumin with piperine”, dropping the qualifier that determines when the caution applies.

Fixes 11/09/2026 22:19

1. 9.5 — “high-dose” qualifier restored: Restored the dropped dose qualifier in the two Key Interactions supplement items, so they now read “high-dose green tea extract” and “high-dose curcumin with piperine”, matching ER l.288 and l.290.
2. 4.5 — Decision-gate items shortened: Trimmed “at or above 1.5× the upper limit of normal” to “at or above 1.5× normal”, “Known hypersensitivity to” to “Hypersensitivity to”, and “Immunosuppressive medications” to “Immunosuppressants”, removing about three wrapped lines from the two gates. The overrun is reduced but not eliminated, because items 8.2, 9.2, 14.2 and 15.2 require every ER contraindication, interaction and biomarker to be carried onto the sheet.

Issues 11/09/2026 22:13

1. 4.5 — Sheet overruns one A4 page: The decision-gate block (11 contraindications at lines 565–575, 14 key interactions at lines 583–596) plus the 10-row Monitoring table, Risks card and Qualitative list push the sheet well past a single A4 page; stop item 2 (line 566, ~190 characters) and the four-drug example lists in caution items (lines 585–588) are the largest contributors.

Fixes 11/09/2026 22:13

1. 4.5 — Contraindication gate condensed: Tightened all 11 stop items without dropping a threshold or qualifier — the four-clause enzyme item collapsed to “ALT, AST, bilirubin or alkaline phosphatase at or above 1.5× the upper limit of normal; GGT at or above 3×”, and “estimated glomerular filtration rate”/”heart-rate-corrected QT interval” shortened to the sheet’s own “eGFR”/”QTcF”, cutting the block from ~1030 to 637 characters.
2. 4.5 — Key Interactions gate condensed: Trimmed the repeated “absolute contraindication in trial” marker to “contraindicated in trial” and cut each example drug list to its two or three lead agents, reducing the block from ~1180 to 850 characters while keeping all 14 items and every severity marker.
3. 4.5 — Protocol, Monitoring and Qualitative trimmed: Shortened action_3_sub, the FVC and DLCO targets (“No established on-treatment target; track change from own baseline” to “No established target; track change from baseline”), the speculative benefits line and two qualitative items to recover further vertical space.